Oruka Therapeutics, Inc.
ORKA
$29.91
$2.087.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.28M | -24.57M | -21.00M | -33.39M | -28.62M |
| Total Depreciation and Amortization | 20.00K | 19.00K | 16.00K | 18.50K | 11.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.26M | 3.70M | 3.15M | 4.26M | 10.53M |
| Change in Net Operating Assets | -602.00K | -2.29M | -3.03M | 5.03M | -9.73M |
| Cash from Operations | -21.60M | -23.15M | -20.87M | -24.08M | -27.82M |
| Capital Expenditure | -99.00K | -34.00K | -13.00K | -35.20K | -171.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -122.35M | 4.89M | 42.88M | -359.93M | -- |
| Cash from Investing | -122.45M | 4.86M | 42.87M | -359.97M | -171.00K |
| Total Debt Issued | -- | -- | -- | 2.27M | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 169.91M | 109.00K | -- | 37.35M | 417.21M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 266.50K | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 449.10K | 6.53M |
| Cash from Financing | 169.91M | 109.00K | -- | 40.34M | 423.74M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.86M | -18.18M | 22.00M | -343.70M | 395.75M |